Effect of Melatonin in treatment of COVID-19

Evaluating the effect of Melatonin in prognosis and clinical improvement in patients with COVID-19: A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200426047206N4

Enrollment

Registered

2020-11-01

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. covid-19

Interventions

Intervention 1: Intervention group: Melatonin supplement at a dose of 18 mg twice a day for 7 days and orally, with standard treatment. Intervention 2: Control group: They will receive the national st

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age between 18-75 year Hospitalized in ward Confirmed diagnosis with PCR Elapsed less than 48 hour from symptom onset Not pregnant or breastfeeding Do not have moderate to severe liver and renal problems. Not treated with immunosuppressive drugs during the last 3 months

Exclusion criteria

Exclusion criteria: Drug intolerance

Design outcomes

Primary

Measure	Time frame
Need to oxygen therapy rate. Timepoint: During treatment. Method of measurement: view patients medical file.;Rate of sleep and depression. Timepoint: Hospital Anxiety and Depression Questionnaire. Method of measurement: Score.;The amount of hospitalization in the intensive care unit during 28 days. Timepoint: Day 28 after treatment. Method of measurement: view patients medical file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Khazaei

Hamedan University of Medical Sciences

salman.khazaei61@gmail.com+98 81 3838 0548

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026